---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-276225"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:29:53.191586+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports positive Phase 2 data for REACT; narrows Phase 3 enrollment; appoints new CEO

## Summary
- Positive interim Phase 2 data: REACT preserved kidney function up to 30 months in high-risk Stage 3b/4 diabetic CKD patients.
- Phase 3 proact 1 protocol modified: eGFR range narrowed to 20-35 ml/min/1.73m2; enrollment paused until H1 2024.
- Manufacturing paused due to QP audit documentation deficiencies; no safety issues; expected to resume H1 2024.
- Bruce Culleton appointed CEO effective Nov 15, 2023; Tim Bertram transitions to scientific advisory role.
- Cash and marketable securities $396M as of Sept 30, 2023; funding into Q4 2025.

## SEC filing metadata
- accession: 0001193125-23-276225
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/d83356d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-276225
- JSON: https://secwatch.observer/filing/0001193125-23-276225.json
- Plain text: https://secwatch.observer/filing/0001193125-23-276225.txt

## Key facts
- Executive change
  Bruce Culleton was appointed as Class III Director at PROKIDNEY CORP..
  - Action: appointed
  - Role: Class III Director
  source text: the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm
- Executive change
  Tim Bertram departed as Director at PROKIDNEY CORP..
  - Action: resign
  - Role: Director
  source text: Dr. Bertram will resign from the Board of Directors (the “Board”) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm
- Executive change
  Bruce Culleton was appointed as Chief Executive Officer at PROKIDNEY CORP..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm
- Executive change
  Tim Bertram departed as Chief Executive Officer at PROKIDNEY CORP..
  - Action: terminated without cause
  - Role: Chief Executive Officer
  source text: the board of directors (the “Board”) of ProKidney Corp. (the “Company”) approved the termination, without cause, of Tim Bertram, Ph.D., Chief Executive Officer of the Company, effective November 15, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.